Simulations Plus, Inc.
SLPSimulations Plus, Inc. (SLP) is a software company specializing in developing pharmacometric and pharmacokinetic modeling and simulation tools for the pharmaceutical, biotech, and health care industries. Founded in 1996, the company provides solutions that aid in drug discovery, development, and regulatory approval processes, with a focus on optimizing clinical trial design and understanding drug behavior. Its flagship products include GastroPlus, ABLAs, and other modeling platforms used by scientists and researchers worldwide.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| August 5, 2024 | $0.06 | 2024-07-29 | 2024-07-29 |
| May 6, 2024 | $0.06 | 2024-04-26 | 2024-04-29 |
| February 5, 2024 | $0.06 | 2024-01-26 | 2024-01-29 |
| November 6, 2023 | $0.06 | 2023-10-27 | 2023-10-30 |
| August 7, 2023 | $0.06 | 2023-07-28 | 2023-07-31 |
Dividends Summary
- Consistent Payer: Simulations Plus, Inc. has rewarded shareholders with 51 dividend payments over the past 12 years.
- Total Returned Value: Investors who held SLP shares during this period received a total of $2.87 per share in dividend income.
- Latest Payout: The most recent dividend of $0.06/share was paid 536 days ago, on August 5, 2024.
- Yield & Schedule: SLP currently pays dividends quarterly with an annual yield of 1.15%.
- Dividend Growth: Since 2012, the dividend payout has grown by 20.0%, from $0.05 to $0.06.
- Dividend Reliability: SLP has maintained or increased its dividend for 46 consecutive payments.
Company News
The Rosen Law Firm has announced investigations into potential securities claims against Trip.com Group Limited following a 17% stock decline after Chinese regulators launched an antitrust probe. The firm is also investigating claims against CoreWeave, Inc. and Simulations Plus, Inc., offering contingency-based representation for affected shareho...
The Rosen Law Firm is investigating potential securities claims on behalf of Simulations Plus shareholders, alleging the company issued materially misleading business information. Simulations Plus reported Q3 2025 sales of $20.4 million, missing consensus estimates of $20.9 million, causing the stock to plummet 25.75% on July 15, 2025. The firm i...
Simulations Plus reported mixed Q4 results with a 6% revenue decline, but provided optimistic fiscal 2026 guidance projecting 0-4% revenue growth and potential AI-driven solutions, leading to a 21.6% stock price increase.
Simulations Plus reported a significant quarterly loss of $67.3 million, missed sales estimates, and initiated a restructuring, causing its stock price to drop 25.76%.
Rosen Law Firm is investigating potential securities claims against Simulations Plus after the company reported Q3 2025 earnings that missed consensus estimates, causing a 25.75% stock price decline.
